Skye Bioscience, Inc. has been advised by its contract manufacturer (CMO) that it has completed the production of SBI-100 Ophthalmic Emulsion (SBI-100 OE) for Skye's Phase 1 clinical trial. The final drug product will be released and available for clinical use in October, following receipt of acceptable results from quality and analytical testing that has been initiated.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.05 USD | -1.63% | +6.45% | +343.01% |
May. 10 | Skye Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 23 | Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Transportation Index | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+343.01% | 344M | |
+33.63% | 50.85B | |
-0.09% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+11.18% | 26.11B | |
-21.95% | 19.13B | |
+8.61% | 13.05B | |
+28.31% | 12.16B | |
+24.73% | 12.08B |
- Stock Market
- Equities
- EMBI Stock
- News Skye Bioscience, Inc.
- Skye Bioscience, Inc. Completes Drug Production for Phase 1 Clinical Study